Multiple Myeloma

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 Ide-cel therapy significantly improved response and progression-free survival compared to standard regimens in triple-class-exposed relapsed and refractory multiple myeloma patients. Relapsed and refractory multiple myeloma (MM) patients with triple-class exposure display suboptimal responses to standard therapies, leading to poor survival outcomes. Idecabtagene vicleucel...

Medically reviewed by Dr. Shani S. Saks, D.O. on August 2, 2023 In this study of multiple myeloma, patients who experienced a complete response had longer survival periods and higher 5-year survival rates compared to non-complete response patients. The development of a unique prediction model based on transcriptome data allowed for the identification of individuals...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 23, 2023 This study found ixazomib to be an effective and feasible maintenance therapy for newly diagnosed multiple myeloma patients, regardless of age or frailty status. Elderly multiple myeloma (MM) patients have reduced survival and quality-of-life (QoL) compared to younger patients due to comorbidities, increased...

In this exclusive MD Newsline webcast Hematology-Oncology Specialists Dr. Mouhammed Kelta and Dr. Shaina Rozell discuss health disparities in Multiple Myeloma. View the webcast here.

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 A real-world data-derived algorithm was determined to be a feasible and accurate method for assessing treatment response in patients with multiple myeloma. Findings suggest that the derived response algorithm can consistently reproduce response assessments in patients with multiple myeloma in a clinical trial...

Isatuximab plus bortezomib, lenalidomide, and dexamethasone is feasible and effective for newly diagnosed multiple myeloma patients who are ineligible or have no intent for autologous stem cell transplantation. Newly diagnosed multiple myeloma (NDMM) patients ineligible for autologous stem cell transplantation (ASCT) have lower survival rates. Bortezomib (trade name Velcade)+lenalidomide (trade name Revlimid)+dexamethasone (VRd) is a...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 The combination of isatuximab, carfilzomib, and dexamethasone was found to be safe and efficacious for the treatment of relapsed multiple myeloma. Triplet regimens consisting of a proteasome inhibitor or immunomodulatory drug, a monoclonal antibody, and dexamethasone have substantially improved clinical outcomes in relapsed...

Multiple myeloma (MM) symptoms are generally nonspecific, according to a study published online June 25 in Cancers. Stella Bowcock, M.D., from the King’s College Hospital NHS Trust in the United Kingdom, and colleagues explored the presenting symptoms to identify early signs of MM and their association with organ damage. Symptoms were recorded in the patients’ own...

A recently published study reveals key factors contributing to the underutilization of treatment in multiple myeloma patients. The study emphasizes the importance of understanding patients’ perceptions, the role of physician recommendations, and individual decision-making preferences. Treatment underutilization in multiple myeloma is influenced by patient perceptions, doctor recommendations, and individual decision-making practices. No racial differences were...